Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma  by Verduzco-Rodríguez, Leonardo et al.
case report
Hematol Oncol Stem Cell Ther 4(4)     Fourth Quarter 2011 hemoncstem.edmgr.com182
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) region are generally incurable. The goals of 
treatment are more limited, and include prolongation 
of overall survival or progression-free survival and pal-
liation of existing symptoms. Response rates to metho-
trexate as high as 77% have been reported in patients 
with no prior treatment. The most widely studied and 
used dosing is weekly intravenous administration of 40 
to 60 mg/m2. Response rates to bleomycin are in the 
15% to 20% range. As early as 1977, cisplatin was found 
to induce rapid responses in 30% of patients who had 
been heavily pretreated with surgery, radiation, and che-
motherapy. Higher response rates were seen in patients 
without prior treatment.
The combination of cisplatin/5-fluorouracil 
emerged as a favored treatment regimen in the 1980s 
and 1990s. This was based initially on phase II trials 
published in the mid-1980s testing induction chemo-
therapy, in which response rates of 67% and 70% with 
complete response rates of 19% and 27% were seen.1
Other new agents were tested in patients with ad-
vanced SCCHN. Both docetaxel and paclitaxel stood 
out as having high single-agent response rates (21% to 
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A 61-year-old male patient with metastatic poorly differentiated squamous cell carcinoma of larynx 
to lymph nodes and lung was treated with a third-line chemotherapy scheme with paclitaxel, nimotu 
zumab and low-dose methotrexate receiving a total of 30 cycles. The response was complete until to-
day and maintained at 16 months. Nimotuzumab is a humanized mono clonal antibody used to treat 
squamous cell carcinomas of the head and neck. This third-line chemotherapy combination with pacli 
taxel-nimotuzumab-methotrexate seems to be an active combination and needs further clinical trials to 
validate its use in heavily treated patients.
42%). In cancers responsive to taxanes, docetaxel and 
paclitaxel are active on both the weekly and every-21-
day schedules. Docetaxel administered every 3 weeks is 
probably more active and associated with more adverse 
events than when administered on a weekly schedule, 
whereas weekly paclitaxel may be better tolerated and 
more efficacious than when administered every 21 
days.2
Examples of new agents (response rates) in the same 
class as historically active agents in SCCHN include if-
osfamide (26%), pemetrexed (26%), oxaliplatin (10%), 
capecitabine (8%) and vinorelbine (6%).7 Active agents 
with novel mechanisms of action or targets include iri-
notecan (14%), cetuximab (13%), gefitinib (11%), and 
erlotinib (4%).7 In a large randomized phase III study 
(TAX 324) comparing cisplatin/docetaxel/fluoro-
uracil (TPF) to cisplatin/fluorouracil (PF), TPF was 
superior to PF in patients with locally ad vanced head 
and neck cancer.3 Unfortunately, it is unclear to what 
extent the use of these agents has brought about mean-
ingful improvement in clinically relevant outcomes in 
this setting. No one agent or regimen is known to sig-
nificantly increase survival compared to other agents. 
Individualized decisions in these circumstances should 
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focus on benefits of palliation versus the risks of treat-
ment toxicity.
CASE 
A 61-year-old male patient was initially diagnosed 
with poorly differentiated squamous cell carcinoma 
(T3N1M0) of the larynx with glottic and infraglottic 
extension and with a right cervical lymph node metas-
tasis of 2 cm. He received initial treatment with radia-
tion therapy (6400 cGy) and concurrent chemotherapy 
with weekly cisplatin for seven weeks in May 2009, with 
a 90% partial response. PET-CT was performed in 
August 2009 with a persistent post-chemoradiotherapy 
tumor without the patient accepting a salvage laryngec-
tomy, so treatment was attempted with a second line 
chemotherapy regimen with 5FU-cisplatin-docetaxel 
and cetuximab as described by Haddad for 4 cycles with 
partial response of 80% by PET-CT.4 
In January 2010 a new laryngoscopy showed edema 
in the right half of the larynx with suspected submucosal 
tumor activity and with a right 2×2 cm cervical lymph 
node, which increased in volume and consistency, sug-
gesting tumor activity. A rescue total laryngectomy and 
right radical neck dissection was performed in February 
2010. Pathology reported a poorly differentiated squa-
mous cell carcinoma extensively affecting the right glot-
tis, subglottis, thyroid cartilage, thyroid gland and soft 
tissue with one level II node metastasis with capsular 
rupture and nine nodes without metastasis. HPV was 
not tested. HIV was negative. The patient received 4 
cycles of postoperative chemotherapy with 5-FU/cis-
platin. In July 2010, the patient presented again with 
tumor activity in the area of the laryngectomy and bi-
lateral neck lymphadenopathy, right axillary adenopathy. 
A new PET-CT scan showed bilateral tumor activity 
in the neck, right axillary adenopathy, left paratracheal 
node and left pulmonary parenchymal metastatic nod-
ule (Figure 1). 
A third-line chemotherapy scheme was given with 
paclitaxel 80 mg/m2 and nimotuzumab 50 mg/m2 IV 
each week for 7 weeks as induction.5,6 Therapy contin-
ued alternating with the same drugs every 15 days and 
methotrexate 25 mg/m2 IM every 15 days as mainte-
nance, receiving a total of 30 cycles.
The response was complete and maintained at 16 
months (December 2011) on the basis of physical ex-
amination and imaging studies according to new PET-
CT with disappearance of the tumor necrosis area, the 
axillary and cervical lymphadenopathy, as well as pulmo-
nary metastases (Figure 2). The toxicity was very mild, 
only neutropenia grade I and peripheral neuropathy 
grade I-II. There was no evidence of skin rash. The pa-
tient was asymptomatic with excellent general condition 
and without any tumor activity on physical examination. 
Figure 1. PET-CT pre-chemotherapy with paclitaxel-
nimotuzumab/methotrexate.
Figure 2.  PET-CT after 20 cycles of chemotherapy with paclitaxel-
nimotuzumab/methotrexate.
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DISCUSSION
Recurrent and/or metastatic HNSCC has a poor 
prognosis, with an overall survival (OS) ranging from 
3 to 4 months when untreated and to 6 to 9 months 
when treated with platinum-based therapy.7 This pa-
tient was treated with one of the best combination of 
drugs (5FU-cisplatin-docetaxel and cetuximab) with-
out complete response. This regimen TPF plus cetux-
imab had a 100% response rate and 80% complete re-
sponse rate in a phase I trial.3
Nimotuzumab (CIMAher, Center of Molecular 
Immunology, Havana, Cuba) is a humanized mono-
clonal antibody used to treat squamous cell carcino-
mas of the head and neck. Like cetuximab,8 nimotu-
zumab binds to the epidermal growth factor recep-
tor (EGFR), a signaling protein that normally con-
trols cell division.This third-line chemotherapy com-
bination with paclitaxel-nimotuzumab-methotrexate 
seems to be an active combination and needs further 
clinical trials to validate its use in heavily treated pa-
tients.
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